Visit Nektar Therapeutics

It’s #AutoimmuneDiseaseAwarenessMonth. Dedicated to developing novel therapies for patients affected by #autoimmunediseases, we are evaluating NKTR-358, our investigational therapeutic candidate, in multiple trials. Learn more: https://t.co/DlOZpO7aap https://t.co/Dm6frUMwDk

This #InternationalWomensDay, we’re saying thank you to all the women on our team developing innovative #immunotherapy treatments! Nektar is also proud to work with organizations supporting the advancement of #WomeninSTEM. #IWD2022 https://t.co/2ifQLW8b9v

In honor of #EmployeeAppreciationDay, we’re celebrating and expressing gratitude for our team! Thanks for your dedication to patients as we advance potential #immunotherapies and for making Nektar a rewarding place to work. Learn more about us: https://t.co/7r76hKbB6Y https://t.co/YqH85HrWIe

We had a great time today at the @SFBusinessTimes #SFBTwomenwholead event and the privilege of hearing from female #biotech leaders. At Nektar, we believe in the importance of promoting opportunities for #womeninSTEM. Hear more from our colleague Wildaliz Nieves, Ph.D. https://t.co/yvv0KIQdvY

We’re pleased to advance investigation of BEMPEG as a treatment for #genitourinary #cancers and join @ASCO #GU22 to highlight our clinical trials in urothelial carcinoma and in renal cell carcinoma. Learn more about our IL-2 #immunotherapy: https://t.co/slOmoYlgle https://t.co/5P7iQlE3YE

Proud partners of the organization, we’re featuring @WomenInBio during #IDWGS 2022. Offering career support, mentorship and training for women in #biotech, they’ve created a diverse and inclusive community of #womeninSTEM. Read more: https://t.co/qKISLuiFCs https://t.co/iQbI7zBADp

This International Day of Women and Girls in Science #IDWGS, we’re celebrating @NexGeneGirls, an organization providing opportunities and mentorship in our local communities. Together, we are empowering the next generation of #girlsinSTEM. Learn more: https://t.co/KzElLDzGYJ https://t.co/clIiGIsevn

Today is #WorldCancerDay. Our team is privileged to work at the cutting edge of science and #oncology to create potential new #cancer therapies for people impacted by these debilitating diseases. Learn about our commitment: https://t.co/JSKX3jSoos https://t.co/LJgYBJphU9

We’re pleased to share a new manuscript in @futuresciencegp on the currently enrolling PIVOT-12 Phase 3 study evaluating BEMPEG (NKTR-214) for adjuvant use in patients with resected #melanoma. Read here: https://t.co/osJsS8jV4A

It’s #NationalMentoringMonth, and we’re celebrating the valuable impact mentors have in #biotech and #STEM. Our team is proud to support the next generation, which you can read about here: https://t.co/Cu0Y8Yn4xV https://t.co/oaUJPli70Y

At #JPM2022 next week, Company management will present on the exciting advances we are making across our #immunooncology and #immunotherapy pipelines. Learn more about our programs: https://t.co/zPoCrgKvWo https://t.co/32GqRiwHV3

We’re excited about the potential of our NKTR-358 program in partnership with @LillyPad to treat #autoimmune disorders and restore the immune system balance with T regulatory cells. Learn more about this first-in-class IL-2 agonist: https://t.co/DlOZpO7aap https://t.co/NFK75cJOPy

Today, our partner @LillyPad presented encouraging new data from a Phase 1b study of our novel T regulatory cell stimulator, NKTR-358, in patients with #atopicdermatitis. Read about these findings’ potential for treating #autoimmune disorders: https://t.co/jBjG0nI3WR https://t.co/TmiXBZCS70

At #ASH21, we presented data for NKTR-255 in patients with hematologic malignancies, including patients with prior CAR-T Therapy. Learn more: https://t.co/fgiLXXHH7z #immunooncology #cancer https://t.co/TCQuTPRTwI

At Nektar, we’re excited about the potential impact NK cell therapies could have on patients with #cancer. Read our @endpts sponsored article to learn about the continued clinical development of our IL-15 agonist, NKTR-255: https://t.co/SvxLmJAfPp #ASH21

The IL-2 pathway can stimulate and regulate anti-tumor #immune responses. Leveraging this approach, we designed NKTR-214 (BEMPEG) to help patients’ systems fight #cancer. Learn more: https://t.co/slOmoYlgle #ESMOImmuno21 #immunooncology https://t.co/DSmd8SKspe

We’re excited to attend #ESMOImmuno21 and present on NKTR-214 (BEMPEG), our lead #immunooncology candidate. View our poster here: https://t.co/fgiLXXHH7z https://t.co/hgZWJmBsqP

Cytokine therapies that stimulate NK cell production have the potential to become the next generation of cancer immunotherapies. Learn how Nektar is harnessing this potential with our IL-15 agonist, NKTR-255 in our new @endpts sponsored article: https://t.co/SvxLmJAfPp

We look forward to the #Cytokine-Based #Cancer Immunotherapies Summit this week. Willem Overwijk, our VP of #Oncology Research, will present on NKTR-255, our investigational IL-15 #immunotherapy, on 12/1 at 2:00 p.m. ET. Register here: https://t.co/fo1rvV1zBE https://t.co/SbJFGgTfja

It’s #LungCancerAwarenessMonth. Learn more from @AmericanCancer why patients and families affected by #lungcancer, including #NSCLC, need new treatment options: https://t.co/DMKrvAwacz #LCAM https://t.co/OlyZ301tcC